Raymond James & Associates’s Evolent Health EVH Stock Holding History

Raymond James & Associates’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$498K	Buy	17,598 +249	+1%	+$6.42K	﹤0.01%	3118
2024 Q2	$332K	Sell	17,349 -4,845	-22%	-$124K	﹤0.01%	3319
2024 Q1	$728K	Sell	22,194 -1,161	-5%	-$37K	﹤0.01%	2812
2023 Q4	$771K	Sell	23,355 -5,138	-18%	-$145K	﹤0.01%	2683
2023 Q3	$776K	Sell	28,493 -15,986	-36%	-$444K	﹤0.01%	2617
2023 Q2	$1.35M	Buy	44,479 +167	+0.4%	+$5.4K	﹤0.01%	2312
2023 Q1	$1.44M	Sell	44,312 -2,968	-6%	-$93.9K	﹤0.01%	2231
2022 Q4	$1.33M	Sell	47,280 -60,479	-56%	-$1.73M	﹤0.01%	2268
2022 Q3	$3.87M	Buy	107,759 +42,018	+64%	+$1.48M	﹤0.01%	1552
2022 Q2	$2.02M	Sell	65,741 -736	-1%	-$21.4K	﹤0.01%	1975
2022 Q1	$2.15M	Sell	66,477 -20,511	-24%	-$537K	﹤0.01%	2083
2021 Q4	$2.41M	Buy	86,988 +10,446	+14%	+$300K	﹤0.01%	2045
2021 Q3	$2.37M	Sell	76,542 -1,966	-3%	-$47.2K	﹤0.01%	1982
2021 Q2	$1.66M	Buy	78,508 +22,893	+41%	+$459K	﹤0.01%	2232
2021 Q1	$1.12M	Buy	55,615 +2,910	+6%	+$55.3K	﹤0.01%	2429
2020 Q4	$845K	Buy	52,705 +9,845	+23%	+$130K	﹤0.01%	2449
2020 Q3	$532K	Sell	42,860 -954	-2%	-$11.2K	﹤0.01%	2575
2020 Q2	$312K	Buy	43,814 +34	+0.1%	+$228	﹤0.01%	2894
2020 Q1	$238K	Buy	43,780 +2,485	+6%	+$22.2K	﹤0.01%	2918
2019 Q4	$374K	Sell	41,295 -6,803	-14%	-$55.3K	﹤0.01%	2945
2019 Q3	$346K	Buy	48,098 +23,542	+96%	+$169K	﹤0.01%	2922
2019 Q2	$195K	Sell	24,556 -6,447	-21%	-$76.3K	﹤0.01%	3275
2019 Q1	$390K	Buy	31,003 +3,202	+12%	+$50.7K	﹤0.01%	2830
2018 Q4	$555K	Buy	27,801 +11,907	+75%	+$275K	﹤0.01%	2482
2018 Q3	$451K	Sell	15,894 -536	-3%	-$12.8K	﹤0.01%	2780
2018 Q2	$346K	Buy	16,430 +257	+2%	+$4.86K	﹤0.01%	2927
2018 Q1	$230K	Buy	16,173 +1,574	+11%	+$22.5K	﹤0.01%	3059
2017 Q4	$180K	Buy	14,599 +17	+0.1%	+$240	﹤0.01%	3094
2017 Q3	$260K	Sell	14,582 -26	-0.2%	-$536	﹤0.01%	2874
2017 Q2	$370K	Buy	+14,608	New	+$351K	﹤0.01%	2593

Other funds holding EVH

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Raymond James & Associates's EVH Position: Q3 2024 in Review

Raymond James & Associates increased its Evolent Health (EVH) stake by 1.4% in Q3 2024, buying an estimated $6.42K and bringing the position to 17,598 shares worth $498K. The position accounts for ﹤0.01% of the portfolio, ranked #3118.

Raymond James & Associates first reported a position in EVH in Q2 2017 and has held it in 30 quarters since. The position peaked at $3.87M in Q3 2022. 262 funds tracked by Wall St. Rank hold EVH as of Q3 2024.

Raymond James & Associates held 17,598 shares of Evolent Health worth $498K as of Q3 2024.
Raymond James & Associates bought 249 Evolent Health shares in Q3 2024, an estimated $6.42K.
Evolent Health made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3118 holding.
Raymond James & Associates first reported a position in Evolent Health in Q2 2017 and has held it in 30 quarters since.
Raymond James & Associates's Evolent Health position peaked at $3.87M in Q3 2022.
262 funds tracked by Wall St. Rank held Evolent Health as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.